EGFR and colonic neoplasm: However, the decision to allow reimbursement appears to have been influenced by strong clinical evidence documented on the FDA drug label, suggesting that testing for overexpression of EGFR contributes to achieving an optimal therapeutic effect in both lung and colon cancers.